Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In total, 554 Thai patients with chronic HCV infection treated with a PEG-IFN-based regimen were enrolled.
|
31565578 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Significant differences were not observed between age- and HCV genotype-stratified patients receiving PEG-IFN α-2a and -α-2b, but α-2b appears to have a modest efficacy advantage over α-2b, particularly in male HCV patients ≥60 years of age.
|
30855203 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We compiled demographic, clinical, and genetic data from 715 chronic hepatitis C virus (HCV) patients treated with pegylated interferon (PEG-IFN) alfa-2a and ribavirin.
|
31070545 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the present analysis is to describe the change in neutrophil count resulting from peglated interferon alpha 2-a (PEG-IFN α-2a) therapy in HCV-infected patients.
|
29872876 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neutropenia is a haematologic disorder commonly reported in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon alfa-2a (PEG-IFN α-2a).
|
29574886 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800-1000 mg/d RBV according to weight orally for 48 weeks.
|
29654010 |
2018 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred and fifty Egyptian patients with HCV genotype 4 treated with PEG-IFN/ribavirin were assessed at 12 and 24 weeks of therapy, the rs12979860 genotype was determined using TaqMan-based quantitative polymerase chain reaction.
|
30450628 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, these results concluded that sofosbuvir with ribavirin and PEG-IFNα-2a are highly efficient in HCV-4a Egyptian patients where a high SVR was achieved (72%).
|
29753376 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database.
|
28202839 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-α (PEG-CIFN) in adults with hepatitis C virus (HCV) infection.
|
28123460 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV.
|
28506030 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the availability of cART, postexposure and pre-exposure prophylaxis (PEP and PrEP) and direct-acting antivirals (DAAs) for HCV, less concern for HIV and HCV might require a new approach to develop effective behavioural intervention strategies among MSM.
|
27789574 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There had been no effective vaccine for HCV; a combination of PEG-Interferon and ribavirin for at least 48 weeks was the standard therapy, but it failed in more than 40% of the patients and has a high cost and serious side effects.
|
28464951 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine whether genetic polymorphisms of genes in the vitamin D pathway are associated with treatment responses to pegylated interferon (PEG-IFN)-based therapy in patients with chronic HCV infection.
|
28415985 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This prospective study investigated the relationship between 2 inosine triphosphatase (ITPA) polymorphisms (rs7270101 and rs1127354) and the efficacy of ribavirin-based antiviral therapy in hepatitis C virus (HCV)-infected Chinese patients.A total of 906 patients diagnosed with chronic hepatitis C receiving pegylated interferon (PEG-IFN) plus ribavirin combination therapy between January 2011 and January 2014 from 5 hepatitis centers in Northeast China were enrolled.
|
28723780 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to assess the safety and efficacy of combined treatment with PEG-IFN-α2b and RBV in Egyptian children and adolescents with genotype 4 (GT4) HCV infection.
|
26406390 |
2016 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to assess the utility of more precise definition of 4(th) week viral load [rapid virological response (RVR)] in predicting sustained virological response (SVR) in HCV genotype 1 patients treated with pegylated-interferon (PEG-IFN) and ribavirin.
|
27450028 |
2016 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This nationwide, multicenter study evaluated patients who were younger than 18 years of age when diagnosed with chronic hepatitis C virus (HCV) infection and were treated with pegylated interferon (PEG-IFN) monotherapy or PEG-IFN/ribavirin (RBV) combination therapy between 2004 and 2013.
|
26825765 |
2016 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data examining the role of IL-10 and IL-18 gene polymorphisms among HCV genotype 4 (G4)-infected Egyptians in response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy are limited.
|
27352267 |
2016 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SPP1 SNPs at -443 C>T and -1748 G>A loci may be useful markers for predicting the response to PEG-IFN-α-2b plus RBV therapy in Egyptian patients with chronic HCV genotype 4 infection.
|
25717047 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred and fifty HCV genotype 3 patients were assessed to study the correlation of IL28B with a therapeutic regimen of PEG-IFN alpha plus ribavirin.
|
25462177 |
2015 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Myanmar.This was a retrospective analysis of data from a single clinic exclusively for gastrointestinal diseases in Yangon, Myanmar.
|
26222859 |
2015 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sustained virological response (SVR) rates to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for recurrent HCV in Genotype 1 (G1) LT recipients have been disappointing (30-40%).
|
25152985 |
2015 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This longitudinal, non-inferiority study compared the efficacy and cost benefit of an All-HCV core antigen assay protocol and a hybrid qtHCV RNA PCR and HCV core Ag assay protocol to the standard All-qtHCV-PCR protocol in chronic HCV G4 patients treated with pegylated interferon (PEG IFN) and ribavirin.
|
26018116 |
2015 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review will focus on the second-wave DAAs including protease inhibitors (PI), nucleotide inhibitors, and NS5B inhibitors combined with PEG-IFN and RBV for both treatment-naïve and treatment-experienced genotype 1 hepatitis C virus (HCV-1) infected patients.
|
25529082 |
2015 |